Search
Fondaparinux
go.drugbank.com/drugs/DB00569ApprovedInvestigationalOnce bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold.
Products: ARIXTRA 10 MG/0.8 ML S.C. ENJEKSIYONLUK COZELTI ICEREN KULLANIMA HAZIR SIRINGA, 10 ADET, ARIXTRA 2.5 MG/0.5 ML ENJEKSIYONLUK SOL.10 KUL.HAZ.SIRINGAPrednisone
go.drugbank.com/drugs/DB00635ApprovedInvestigationalVet approved[L10502] Prednisone was granted FDA approval on 21 February 1955.[L10496]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 InducersProducts: Rectodelt 100 mg Zäpfchen, PredniSONE Tablets, USP, 10 mgChlorpropamide
go.drugbank.com/drugs/DB00672ApprovedWithdrawnUp to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. … Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesProducts: ORBİN 250 MG TABLET, 100 ADET, ORBIN 250 MG TABLET, 1000 ADETRupatadine
go.drugbank.com/drugs/DB11614ApprovedInvestigationalRupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria … It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and liquid formulation for pediatric use.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesProducts: RUFTAN 10 MG TABLET, 20 ADET, RUPAFIN® 10 MGAbiraterone
go.drugbank.com/drugs/DB05812ApprovedInvestigational[L54773,L54768] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability … [A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsProducts: Abirateron Sandoz 1000 mg – Filmtabletten, Abirateron 1A Pharma 1000 mg – FilmtablettenCiclopirox
go.drugbank.com/drugs/DB01188ApprovedInvestigationalCiclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective ...
Mixtures: Ciclopirox 3% / Itraconazole 5% / Urea 20%Products: NIBULEN 10 MG/G VAJİNAL KREM, 30 G, NIBULEN 10 MG/ML DERMAL ÇÖZELTİ, 20 MLColchicine
go.drugbank.com/drugs/DB01394ApprovedInvestigationalColchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus."[A183611] Its use was first approved by the FDA in 1961. … [L47591] It has also been investigated in other inflammatory and fibrotic conditions.[A183602]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InhibitorsProducts: COLCHICUM DISPERT 0,5 MG FILM TABLET, 50 ADET, COLCHICINE TABLET 500 mcgPyrazinamide
go.drugbank.com/drugs/DB00339ApprovedInvestigationalA pyrazine that is used therapeutically as an antitubercular agent.
Mixtures: RIFAMPICIN 75 MG/ISONIAZID 50 MG/PYRAZINAMIDE 150 MG, RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400 MG/ETHAMBUTOL 275 MGProducts: PIRAZINID 500 MG TABLET, 50 ADET, PİRAZİNİD 500 MG TABLET, 500 ADETBuprenorphine
go.drugbank.com/drugs/DB00921ApprovedIllicitInvestigationalVet approved[A186263,A186266,A186269] Buprenorphine acts as a partial mu-opioid receptor agonist with a high affinity for the receptor, but lower intrinsic activity compared to other full mu-opioid agonists such … Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.
Mixtures: Suboxone 8 mg/2 mg sublingual tablets, Suboxone 2 mg/0.5 mg sublingual tabletsCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C18 SubstratesDaratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigational[A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. … [A199002] Daratumumab was granted FDA approval on 16 November 2015.
Products: DARZALEX 100 MG/5 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, DARZALEX 400 MG/20 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE